合成了一系列带有磺酰胺部分的卤代4-噻唑烷酮衍生物,并通过FT-IR,1 H NMR,13 C NMR,HRMS和单晶X射线分析对其进行了表征。筛选了新合成的目标化合物对HepG2和MDA-MB-231细胞系的体外细胞毒性,以及抗微生物和抗结核活性。这些化合物对MDA-MB-231细胞系显示出有希望的抗癌活性,对氯取代(6i)和对羟基取代(7e)的三氯衍生物表现出优异的抗癌活性。化合物6b和观察到7c是中等抗菌剂。进一步研究了七种最有效的抗癌药对结核分枝杆菌的抗结核活性,发现化合物7e表现出显着的抗结核活性。还测试了强效候选物对人RBC细胞的溶血活性,发现无毒。针对有效抗癌分子Aurora激酶(PDB ID:4ZTR)的分子对接研究进一步支持了观察到的抗癌活性的作用方式。进一步进行了分子动力学(MD)模拟,以研究配体-蛋白质复合物的稳定性。
[EN] SELECTIVE INHIBITORS OF 12(S)-LIPOXYGENASE (12-LOX) AND METHODS FOR USE OF THE SAME [FR] INHIBITEURS SÉLECTIFS DE 12(S)-LIPOXYGÉNASE (12-LOX) ET PROCÉDÉS D'UTILISATION CORRESPONDANTS
polyhydroxylated aromatics based on caffeic acid phenethyl ester were designed and synthesized as HIV-1 integrase (IN) inhibitors. Most of these compounds inhibited IN catalytic activities in low micromolar range. Among these new analogues, compounds 9e and 9f were the most potent IN inhibitors with IC(50) value of 0.7 μM against strand transfer reaction. Their key structure-activityrelationships were also
Synthesis and SAR of novel, 4-(phenylsulfamoyl)phenylacetamide mGlu4 positive allosteric modulators (PAMs) identified by functional high-throughput screening (HTS)
作者:Darren W. Engers、Patrick R. Gentry、Richard Williams、Julie D. Bolinger、C. David Weaver、Usha N. Menon、P. Jeffrey Conn、Craig W. Lindsley、Colleen M. Niswender、Corey R. Hopkins
DOI:10.1016/j.bmcl.2010.07.007
日期:2010.9
Herein we disclose the synthesis and SAR of a series of 4-(phenylsulfamoyl)phenylacetamide compounds as mGlu4 positive allosteric modulators (PAMs) that were identified via a functional HTS. An iterative parallel approach to these compounds culminated in the discovery of VU0364439 (11) which represents the most potent (19.8 nM) mGlu4 PAM reported to date.
Selective inhibitors of 12(S)-lipoxygenase (12-LOX) and methods for use of the same
申请人:THE REGENTS OF THE UNIVERSITY OF MICHIGAN
公开号:US11236044B2
公开(公告)日:2022-02-01
Disclosed herein are small molecule inhibitors of 12(S)-Lipoxygenase (12-LOX), and methods of using the small molecules to inhibit 12-LOX activation and to treat diseases, such as platelet hemostasis and thrombosis. In particular, disclosed herein are compounds of Formula (I) and pharmaceutically acceptable salts thereof: wherein the substituents are as described.
SELECTIVE INHIBITORS OF 12(S)-LIPOXYGENASE (12-LOX) AND METHODS FOR USE OF THE SAME
申请人:The Regents Of The University Of Michigan
公开号:EP3781548A1
公开(公告)日:2021-02-24
SELECTIVE INHIBITORS OF 12(S)- LIPOXYGENASE (12-LOX) AND METHODS FOR USE OF THE SAME
申请人:THE REGENTS OF THE UNIVERSITY OF MICHIGAN
公开号:US20210147348A1
公开(公告)日:2021-05-20
Disclosed herein are small molecule inhibitors of 12(S)-Lipoxygenase (12-LOX), and methods of using the small molecules to inhibit 12-LOX activation and to treat diseases, such as platelet hemostasis and thrombosis. In particular, disclosed herein are compounds of Formula (I) and pharmaceutically acceptable salts thereof: wherein the substituents are as described.